-

Eureka Therapeutics Announces Upcoming Conference Presentations

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced that the company is scheduled to present at the following March healthcare conferences:

Cowen 40th Annual Health Care Conference
Title: ARTEMIS® Antibody TCR T Cell Therapies for Solid Tumors
Speaker: Hanzhong Li, Ph.D., Senior Vice President of Corporate Strategy
Location: Boston Marriott Copley Place, Boston, MA
Date: Wednesday, March 4, 2020
Time: 8:30 a.m. EST

BioProcess International US West
Title: Optimizing Viral Vector Production
Speaker: Nicole Nunez, Ph.D., Process Development Scientist
Location: Santa Clara Convention Center, Santa Clara, CA
Date: Wednesday, March 11, 2020
Time: 1:05 p.m. PST

About Eureka Therapeutics, Inc.

Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® AbTCR T cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).

Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.

Contacts

Investors
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-722-8720
IR@eurekainc.com

Media
KKH Advisors
Kimberly Ha
917-291-5744
kimberly.ha@kkhadvisors.com

Industry:

Eureka Therapeutics, Inc.

Release Versions
English

Contacts

Investors
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-722-8720
IR@eurekainc.com

Media
KKH Advisors
Kimberly Ha
917-291-5744
kimberly.ha@kkhadvisors.com

More News From Eureka Therapeutics, Inc.

U.S. FDA Grants RMAT Designation to ECT204, an ARTEMIS® CAR (AbTCR) T-Cell Therapy for Advanced Hepatocellular Carcinoma

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company advancing next-generation T-cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ECT204, a GPC3-targeting ARTEMIS® CAR T-cell therapy, for the treatment of patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer. The RMAT designation followed the F...

Eureka’s ARTEMIS® CAR T Cells Show Breakthrough Potential in Solid Tumors in NCI-Led Study Published in Cell Reports Medicine

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled “Antibody–Gamma/Delta T Cell Receptors Targeting GPC2 Regress Neuroblastoma with Low Antigen Density” in Cell Reports Medicine. The study, led by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, demonstrated that Eureka’s ARTEMIS® CAR T cel...

Eureka Therapeutics Appoints Dr. Reginald Seeto and William S. Solari III to Board of Directors

EMERYVILLE, Calif.--(BUSINESS WIRE)--Eureka Therapeutics, Inc., a clinical-stage biotechnology company pioneering safer and more effective T-cell therapies, today announced the appointment of Dr. Reginald Seeto and William S. Solari III to its Board of Directors. Dr. Seeto is a global leader in biopharmaceuticals and diagnostics with expertise in corporate strategy, business development, and operations. He currently serves as President and CEO of Scipher Medicine. Previously, he was President a...
Back to Newsroom